Innovent Biologics Inc
01801: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HKD 53.10 | Nlf | Bwhjgwdxw |
Innovent’s Interim Results in Line, Expecting Sentiment to Improve Despite Declining PD-1 Sales
Narrow-moat Innovent’s results were in line with our expectations. Despite price cuts for other PD-1 drugmakers starting in March, we estimate Tyvyt sales were CNY 1.4 billion in the six months, which is admirable. We estimate biosimilar sales were CNY 463 million (25% of product sales), compared with only CNY 77 million in the second half of last year (5% of product sales).